Transphosphorylation of kinase-dead HER3 and breast cancer progression: A new standpoint or an old concept revisited?

Breast Cancer Research

Volumn 9, Issue 5, 2007, Pages

  Menendez, Javier A ^a   Lupu, Ruth ^b  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3;

BREAST TUMOR; DISEASE COURSE; EDITORIAL; FEMALE; HUMAN; METABOLISM; PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; PHOSPHORYLATION; RECEPTOR, ERBB-3;

EID: 40449116422     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1773     Document Type: Note

References (31)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001, 2:127-137. 10.1038/35052073, 11252954.
2. Herbst RS, Fukuoka M, Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 2004, 4:956-965. 10.1038/nrc1506, 15573117.
3. Blagosklonny MV, Darzynkiewicz Z. Why Iressa failed: Toward novel use of kinase inhibitors (outkook). Cancer Biol Ther 2003, 2:137-140.
4. Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 2005, 12:S135-S144. 10.1677/erc.1.01059, 16113090.
5. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354. 10.1038/nrc1609, 15864276.
6. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441. 10.1038/nature05474, 17206155.
7. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 1995, 14:4267-4275. 394510, 7556068.
8. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999, 18:2149-2164. 1171299, 10205169, 10.1093/emboj/18.8.2149.
9. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The erbB2/erbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100:8933-8938. 166416, 12853564, 10.1073/pnas.1537685100.
10. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3-kinase and Akt is required for antibody-mediated effects of p27, cyclin D1, and antitumor action. Cancer Res 2002, 62:4132-4141.
11. Menendez JA, Mehmi I, Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 2006, 24:3735-3746. 10.1200/JCO.2005.04.3489, 16847284.
12. Arteaga CL. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?. J Clin Oncol 2006, 24:3722-3725. 10.1200/JCO.2006.06.5268, 16847283.
13. Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GN, Bacus SS. The efficacy of herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 2004, 91:1190-1194.
14. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, et al. A small molecule-interaction map for clinical kinase inhibitors. Nat Biotechnol 2005, 23:329-336. 10.1038/nbt1068, 15711537.
15. Spector N, Xia W, El-Hariry I, Yarden Y, Bacus S. HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res 2007, 9:205. 1868927, 17338834, 10.1186/bcr1652.
16. Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002, 62:3151-3158.
17. Atlas E, Bojanowski K, Mehmi I, Lupu R. A deletion mutant of Heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity. Oncogene 2003, 22:3441-3451. 10.1038/sj.onc.1206410, 12776196.
18. Menendez JA, Mehmi I, Lupu R. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. Int J Oncol 2005, 26:649-659.
19. Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res 2003, 1:165-175.
20. Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 2003, 22:761-768. 10.1038/sj.onc.1206130, 12569369.
21. Schaefer KL, Brachwitz K, Braun Y, Diallo R, Wai DH, Zahn S, Schneider DT, Kuhnen C, Vollmann A, Brockhoff G, et al. Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue. Neoplasia 2006, 8:613-622. 1601931, 16867224, 10.1593/neo.06238.
22. Yuste L, Montero JC, Esparis-Ogando A, Pandiella A. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signalling and sensitivity to herceptin. Cancer Res 2005, 65:6801-6810. 10.1158/0008-5472.CAN-04-4023, 16061662.
23. Offterdinger M, Schofer C, Weipoltshammer K, Grunt TW. cerbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol 2002, 157:929-939. 10.1083/jcb.200109033, 12045181.
24. Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa™)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (review). Int J Mol Med 2007, 20:3-10.
25. Golding M, Ruhrberg C, Sandle J, Gullick WJ. Mapping nucleolar and spliceosome localization sequences of neuregulin1-3. Exp Cell Res 2004, 299:110-118. 10.1016/j.yexcr.2004.05.028, 15302578.
26. Breuleux M, Schoumacher F, Rehn D, Kung W, Mueller H, Eppenberger U. Heregulins implicated in cellular functions other than receptor activation. Mol Cancer Res 2006, 4:27-37. 10.1158/1541-7786.MCR-05-0016, 16446404.
27. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK, Kumar R. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 2001, 3:30-37. 10.1038/35050532, 11146623.
28. Chinnaiyan P, Varambally S, Tomlins SA, Ray S, Huang S, Chinnaiyan AM, Harari PM. Enhancing the antitumor activity of ErbB blockade with histone deactylase (HDAC) inhibition. Int J Cancer 2006, 118:1041-1050. 10.1002/ijc.21465, 16152586.
29. de Alava E, Ocana A, Abad M, Montero JC, Esparis-Ogando A, Rodriguez CA, Otero AP, Hernandez T, Cruz JJ, Pandiella A. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 2007, 25:2656-2663. 10.1200/JCO.2006.08.6850, 17602072.
30. Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI. Heregulin beta 1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res 2007, 9:R50. 10.1186/bcr1754, 17686159.
31. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of non-target HER3. Br J Cancer 2007, 97:453-457. 10.1038/sj.bjc.6603910, 17667926.